Recurrent Cancer Clinical Trial
Official title:
A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer
PredoSTAR is a multicenter, randomized, open-label phase II study proposed to patients at high risk of SPC and in whom the treatment of the FPC does not include immunotherapy. Dostarlimab treatment will be started within 6 months after the completion of treatment for localized FPC (i.e. after the end of last CT, RT cure or surgery with a wash-out period of 4 weeks before to start Dostarlimab). Eligible patients will be randomized (1:1) to receive: - Arm Dostarlimab : 4 intravenous (IV) injections of dostarlimab, Q3W or - Arm No treatment
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Recruiting |
NCT05415475 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT04596865 -
Recurrence After Whipple's (RAW) Study
|
||
Recruiting |
NCT06103617 -
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT05364905 -
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
|
||
Recruiting |
NCT05396300 -
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT03441100 -
TCR-engineered T Cells in Solid Tumors: IMA202-101
|
Phase 1 | |
Recruiting |
NCT05359445 -
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03686124 -
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04889742 -
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
|
Phase 2 | |
Recruiting |
NCT05189054 -
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
|
||
Completed |
NCT03132038 -
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT06208657 -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02410187 -
SBRT for Extra-cranial Oligorecurrent Tumor
|
Phase 2 | |
Not yet recruiting |
NCT04784221 -
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse
|
Phase 2 | |
Recruiting |
NCT05626829 -
Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT03941262 -
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
|
Phase 1 | |
Recruiting |
NCT06372574 -
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
|
Phase 1 | |
Completed |
NCT05200195 -
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
|
||
Completed |
NCT03760952 -
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
|